
Available products for licensing and manufacturing — finished dosage forms (FDF), APIs and intermediates.
Product Catalog
Filter by product line. Listings without a line tag appear under "All".
Search in table
100 of 100 products
Product | Strength | Dosage form | Market | Offer type | Contact |
|---|---|---|---|
Injectables for early phase clinical trials https://eramol.com/clinical-services/sterile-manufacturing/aseptic/ | Global | Supply, Marketing Authorization (MA), Tech transfer, Dossier | |
Linaclotide (CAS: 851199-59-2) | — | — | |
Nifedipine (CAS: 21829-25-4) | — | — | |
Azithromycin | Mexico | Dossier | |
Erythromycin | CIS countries | Dossier | |
Isosorbide Mononitrate (Diluted with Lactose) (USP/IP/Ph. Eur) - 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% (CAS: 16051-77-7) | — | — | |
Paracetamol, solution for infusion, 10 mg/ml, 100 ml in a bottle | European Union (EU) | Dossier | |
Rivaroxaban, film-coated tablets, 2,5 mg, 10 mg, 15 mg, 20 mg | European Union (EU) | Dossier | |
Desloratadine, syrup, 0,5 mg/ml | European Union (EU) | Dossier | |
Drotaverine, solution for injection, 20 mg/ml, 2 ml in an ampule | European Union (EU) | Dossier | |
Dexamethasone, solution for injection, 4 mg/ml, 1 ml in an ampule | European Union (EU) | Dossier | |
Moxifloxacin Hydrochloride, solution for infusion, 400 mg, 250 ml in a bottle | European Union (EU) | Dossier | |
Metronidazole, solution for infusion, 5 mg/ml, 100 ml in a vial | European Union (EU) | Dossier | |
Sodium chloride, solution for infusion 100 ml, 200 ml, 250 ml, 400 ml, 500 ml in a vial | European Union (EU) | Dossier | |
Fluconazole, solution for infusion, 2 mg/ml, 100 ml in a bottle | European Union (EU) | Dossier | |
Sorbitol, Sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium lactate, solution for infusion 200 ml in a bottle | European Union (EU) | Dossier | |
Magnesium sulfate, solution for injection, 250 mg/ml | European Union (EU) | Dossier | |
Benzydamine Hydrochloride, oral spray, 1.5 mg/ml, 3.0 mg/ml | European Union (EU) | Dossier | |
Benzydamine Hydrochloride, oral solution, 1.5 mg/ml | European Union (EU) | Dossier | |
Xylometazoline, metered dose nasal spray,1.0 mg/ml, 0.5 mg/ml | European Union (EU) | Dossier | |
Dequalinium chloride, Cinchocaine hydrochloride, lozenges | European Union (EU) | Dossier | |
Doxylamine, oral drops, 15 mg/0.6 ml | European Union (EU) | Dossier | |
Doxylamine, coated tablets, 15 mg | European Union (EU) | Dossier | |
Dexmedetomidine hydrochloride, concentrate for solution for infusion, 100 m g/ml | European Union (EU) | Dossier | |
Atracurium besylate, solution for injection, 10 mg/ml | European Union (EU) | Dossier | |
Meloxicam, tablets, 7,5 mg, 15 mg | European Union (EU) | Dossier | |
Meloxicam, solution for injection, 15 mg | European Union (EU) | Dossier | |
Etoricoxibe, film-coated tablets, 60 mg, 90 mg, 120 mg | European Union (EU) | Dossier | |
Dexketoprofen, solution for injection, 50 mg/2 ml | European Union (EU) | Dossier | |
Ibuprofen, Levomenthol, gel, 50 mg/30 mg | European Union (EU) | Dossier | |
Ibuprofen, film-coated tablets, 200 mg, 400 mg | European Union (EU) | Dossier | |
Valsartan, film-coated tablets, 80 mg, 160 mg | European Union (EU) | Dossier | |
Furosemide, solution for injections, 10 mg/ml | European Union (EU) | Dossier | |
Perindopril, Indapamide, Amlodipine tablets, 4 mg/1.25 mg/5 mg; 4 mg/1.25 mg/10 mg; 8 mg/2.5 mg/5 mg; 8 mg/2.5 mg/10 mg | European Union (EU) | Dossier | |
Lisinopril tablets 10 mg, 20 mg | European Union (EU) | Asset sale | |
Eplerenone film-coated tablets, 25 mg, 50 mg | European Union (EU) | Asset sale | |
Perindopril, Indapamide tablets, 4 mg/1.25 mg, 8 mg/2.5 mg | European Union (EU) | Dossier | |
Acetylsalicylic acid film-coated tablets, 75 mg, 150 mg | MENA, APAC, CIS | Asset sale | |
Oral solid dose for clinical trials https://eramol.com/clinical-services-category/non-sterile-manufacturing/ | Global | Supply, Dossier, Marketing Authorization (MA), Tech transfer | |
Insulin (CAS: 11061-68-0) | — | — | |
ANTICOAGULANT SODIUM CITRATE 4% 250 ml | North America (USA, Canada, Mexico) | Supply | |
Calcium D-Pantothenate (CAS: 137-08-6) | — | — | |
Nitrendipine 10mg tablets (CAS: 39562-70-4) | — | — | |
Isosorbide Dinitrate (Diluted with Lactose) (USP/IP/ Ph. Eur) - 40% (CAS: 87-33-2) | — | — | |
Urapidil Hydrochloride 30mg Oral preparations (CAS: 64887-14-5) | — | — | |
10-Methoxy Iminostilbene (CAS No: 4698-11-7) (CAS: 4698-11-7) | — | — | |
Erythromycin Ethyl Succinate (CAS: 1264-62-6) | — | — | |
Finerenone 10mg tablets (CAS: 1050477-31-0) | — | — | |
2-Cyano phenothiazine (CAS No: 38642-74-9) (CAS: 38642-74-9) | — | — | |
Erythromycin Estolate (CAS: 3521-62-8) | — | — | |
Sitagliptin Phosphate Monohydrate 25 mg Film-coated Tablets (CAS: 654671-77-9) | — | — | |
Cypionic Acid (3-Cyclopentylpropionic Acid) (CAS No: 140-77-2) (CAS: 140-77-2) | — | — | |
2-acetyl-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (CAS: 1095825-46-9) | — | — | |
Erythromycin Stearate (CAS: 643-22-1) | — | — | |
Empagliflozin 10 mg Film-coated Tablets (CAS: 864070-43-9) | — | — | |
Glimepiride 1 mg Tablets (CAS: 93479-97-1) | — | — | |
Difluoro-bromo-Aniline (CAS No: 67567-26-4) (CAS: 4698-11-7) | — | — | |
F-moc Osu (CAS: 82911-69-1) | — | — | |
Pitavastatin Calcium 1mg Film-coated Tablets (CAS: 147526-32-7) | — | — | |
Fmoc-Trp(N-CH2COOAll)-OH (CAS: 2883650-94-8) | — | — | |
Clofibrate 100mg Capsules (CAS: 637-07-0) | — | — | |
Fmoc-Asp(OMpe)-OH (CAS: 180675-08-5) | — | — | |
Diclofenac Sodium 25mg tablets (CAS: 15307-79-6) | — | — | |
Fmoc-Ser(tBu)-Ser[Psi(Me,Me)Pro]-OH (CAS: 1000164-43-1) | — | — | |
Febuxostat 20 mg Film-coated Tablets (CAS: 144060-53-7) | — | — | |
Celecoxib 50mg Capsules (CAS: 169590-42-5) | — | — | |
9-Fluorenyl methanol (CAS No: 24324-17-2) (CAS: 24324-17-2) | — | — | |
Trimebutine maleate (CAS: 34140-59-5) | — | — | |
Lysine Acetylsalicylate (Non-Sterile/Sterile) 100mg Tablets (CAS: 62952-06-1) | — | — | |
Gastrodin 25mg Tablets (CAS: 62499-27-8) | — | — | |
Cyclopentylpropionyl Chloride (CAS No: 104-97-2) (CAS: 104-97-2) | — | — | |
Salcaprozate sodium - SNAC (CAS: 203787-91-1) | — | — | |
Antipyrine 270mg tablets (CAS: 60-80-0) | — | — | |
Tofacitinib Citrate 5mg Tablets (CAS: 540737-29-9) | — | — | |
7-Ethyl tryptophol (CAS No: 41340-36-7) (CAS: 41340-36-7) | — | — | |
5-butyl-1H-benzotriazole (CAS: 3663-24-9) | — | — | |
Benorilate 500mg Tablets (CAS: 5003-48-5) | — | — | |
Avibactam Sodium 2g Injection (CAS: 1192491-61-4) | — | — | |
Dimethyl Isosorbide (CAS No: 5306-85-4) (CAS: 5306-85-4) | — | — | |
Voriconazole 50mg Tablets (CAS: 137234-62-9) | — | — | |
Nicotinylmethylamide 500mg Tablets (CAS: 3569-99-1) | — | — | |
Diclofenac Potassium 12.5mg Tablets (CAS: 15307-81-0) | — | — | |
Aceclofenac 50mg Tablets (CAS: 89796-99-6) | — | — | |
Indobufen 200mg tablets (CAS: 63610-08-2) | — | — | |
Ambroxol Hydrochloride 30mg Tablets (CAS: 23828-92-4) | — | — | |
Ammonium Chloride 300mg Tablets (CAS: 12125-02-9) | — | — | |
Vonoprazan Fumarate 10mg Tablets (CAS: 2127152-98-9) | — | — | |
Pantoprazole Sodium 20 mg tablets (CAS: 164579-32-2) | — | — | |
Dihydroxyaluminium Aminoacetate 250mg Tablets (CAS: 41354-48-7) | — | — | |
Rabeprazole Sodium 10mg Delayed-Release Tablets (CAS: 117976-90-6) | — | — | |
Esomeprazole Sodium 40mg Injection (CAS: 119141-88-7) | — | — | |
Glycine 100mg Sublingual Tablets (CAS: 56-40-6) | — | — | |
L-Lysine Hydrochloride 100mg Tablets (CAS: 10098-89-2) | — | — | |
Phenprobamate 200mg tablets (CAS: 63-91-2) | — | — | |
Aceglutamide 100mg Injection (CAS: 2490-97-3) | — | — | |
Vitamin E 5mg Tablets (CAS: 2074-53-5) | — | — | |
Acetomenadione 2mg Tablets (CAS: 546-88-3) | — | — | |
Gentamicin Sulfate 40mg Injection (CAS: 1405-41-0) | — | — | |
Oxytetracycline 125mg Tablets (CAS: 79-57-2) | — | — | |
Lincomycin Hydrochloride 250mg Tablets (CAS: 859-18-7) | — | — |
Explore pharma products for licensing and distribution
The demand for pharma products for licensing continues to grow as companies seek faster ways to expand portfolios, secure distribution rights, and accelerate entry into regulated markets. MAI CDMO Network offers a searchable pharmaceutical product list where every record includes the essential fields: product name, strength, dosage form, market, and offer type. This structure allows portfolio managers, distributors, and business development teams to easily find opportunities for in-licensing, MA/MAH licensing, dossier licensing, and CDMO manufacturing.
Searchable product data
The system is designed to give buyers clear and actionable information:
⬢ Product name + strength + dosage form: for example, "Amoxicillin 500 mg tablets" or "Atorvastatin 20 mg capsules."
⬢ Market: a dropdown selector covering global regions and key countries.
⬢ Offer type: choose whether the listing is manufacturing only, distribution rights only, marketing authorization (MA), or combinations such as MA + Manufacturing and MA + Distribution rights.
Markets covered in detail
Licensing opportunities are not limited to one geography. MAI CDMO Network covers a broad spectrum of territories, allowing users to filter by region or key country:
⬢ Global: products available for worldwide licensing and distribution.
⬢ European Union (EU): suitable for centralized or decentralized EMA submissions.
⬢ European Economic Area (EEA): extending coverage beyond the EU to additional European markets.
⬢ North America (USA, Canada, Mexico): includes FDA and Health Canada compliant dossiers and distribution opportunities.
⬢ Latin America (LATAM): markets like Brazil, Argentina, and Mexico with growing demand for generic drugs for licensing.
⬢ Middle East & North Africa (MENA): regional authorizations and distribution rights adapted to local agencies.
⬢ Sub-Saharan Africa: diverse opportunities for essential medicines and ready-to-license pharmaceuticals.
⬢ Asia-Pacific (APAC): fast-growing markets such as China, India, Japan, and Australia.
⬢ CIS countries: including Russia and neighboring markets with specific regulatory frameworks.
Key individual markets are also listed for more precise targeting: United States, Canada, Mexico, Brazil, Argentina, United Kingdom, Germany, France, Italy, Spain, China, India, Japan, and Australia. This granularity makes it possible to match pharmaceutical licensing opportunities to your exact territory needs.
Types of offers available
Each listing specifies the offer type so you can identify what is on the table:
⬢ Manufacturing only: contract manufacturing without licensing or distribution rights.
⬢ Distribution rights only: commercial rights to sell in defined territories.
⬢ Marketing Authorisation (MA): access to an existing MA or the ability to license it.
⬢ Manufacturing + Distribution rights: supply plus sales authorization in chosen markets.
⬢ MA + Manufacturing: licensing of the authorization combined with production rights.
⬢ MA + Manufacturing + Distribution rights: a complete package including regulatory, supply, and commercialization.
This transparent categorization helps companies quickly evaluate whether a product is aligned with their business model, whether that means sourcing from a CDMO, obtaining distribution rights, or acquiring marketing authorization licensing.
Benefits for different users
The MAI CDMO Network licensing catalog is designed for:
⬢ Pharma companies: to expand their pipeline with in-licensed assets and accelerate market entry.
⬢ Distributors: to secure distribution rights in their regions with minimal lead time.
⬢ CDMOs and manufacturers: to showcase products where they can provide manufacturing services.
⬢ Startups and smaller firms: to use dossier licensing plus CDMO manufacturing for quick launches.
Why use MAI CDMO Network
By consolidating pharma products for licensing into one searchable database, MAI CDMO Network reduces the time and complexity of identifying new opportunities. The structure � product name, strength, dosage form, market, and offer type � provides clarity and comparability. Whether you are seeking MA/MAH licensing, dossier licensing, or distribution rights, the platform makes it simple to find, filter, and connect with the right partner. With global coverage spanning EU, EEA, North America, LATAM, MENA, Sub-Saharan Africa, APAC, CIS, and key countries such as US, UK, Germany, China, India, Japan and more, this catalog is your gateway to ready-to-license pharmaceuticals worldwide.
Get started today
Use MAI CDMO Network to search for pharma products for licensing by product name, strength, dosage form, target market, and offer type. Explore opportunities across EMA, FDA and other regulatory territories, and find the right mix of manufacturing, distribution rights, and MA/MAH licensing to expand your business.